
    
      Main objective of the trial:

      The main objective of the trial is to evaluate progression-free survival (PFS) in the
      heregulin (HRG) high expression population from subjects treated with patritumab + cetuximab
      + platinum-based therapy compared to placebo + cetuximab + platinum-based therapy.
    
  